Juno Therapeutics Gmbh

Editas Medicine, Inc.

Abvitro LLC

Yue Jiang

Stephen Jacob Goldfless

Brian J Belmont

Francois Vigneault

Adrian Wrangham Briggs

Cameron Brandt

Rupesh Amin

Collin Hauskins

Blythe D Sather

Melissa Works

Aye Chen

Alexandra Croft

Michael Ports

Gordon Grant Welstead

Stephen Michael Burleigh

Timothy G Johnstone

Christopher Heath Nye

David Jeffrey Huss

Dean Y Toy

James Sissons

Haley Peper

Stanley R Frankel

Heidi Jessup

Jim Shi Xiang Qin

David Koppstein

Hieu Nguyen

Catherine Sierra

Sonia Timberlake

Eric Jeffery

Yeonjoo Oh

Queenie Vong

Ronald Hause

Neha Soni

Christopher Borges

Andreia Costa

Jens Hasskarl

Rajagopal Chari

Michael Pourdehnad

Jenna Bailey

Samriti Bedi

Madeline Williams

François Vigneault

Provided are receptor tyrosine kinase-like orphan receptor 1 (ROR1)-binding molecules, in particular, to human antibodies specific for ROR1, including antibody fragments. The present disclosure further relates to recombinant receptors, including chimeric antigen receptors (CARs) that contain such antibodies or fragments, and polynucleotides that encode the antibodies, antigen-binding fragments or receptors specific for ROR1. The disclosure further relates to genetically engineered cells, containing such ROR1-binding proteins and receptors, and related methods and uses thereof in adoptive cell therapy.

Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ROR1)

The present disclosure relates in some aspects to methods, compositions and uses involving immunotherapies, such as adoptive cell therapy, e.g., T cell therapy, and an immunomodulatory compound, such as a structural or functional analog or derivative of thalidomide and/or an inhibitor of E3-ubiquitin ligase. The provided methods, compositions and uses include those for combination therapies involving the administration or use of one or more immunomodulatory compounds in conjunction with a T cell therapy, such as a genetically engineered T cell therapy involving cells engineered with a recombinant receptor, such as chimeric antigen receptor (CAR)-expressing T cells. Also provided are compositions, methods of administration to subjects, articles of manufacture and kits for use in the methods. In some aspects, features of the methods and cells provide for increased or improved activity, efficacy, persistence, expansion and/or proliferation of T cells for adoptive cell therapy or endogenous T cells recruited by immunotherapeutic agents.

Methods and combinations for treatment and T cell modulation

Provided herein are methods for target gene sequencing and single cell barcoding in conjunction with analysis of gene expression in single cells. In some embodiments, the target gene is an immune molecule, such as an antibody or TCR. In some embodiments, the methods can be used to carry out transcriptome sequencing, e.g., RNA sequencing, to capture transcriptome of single cells paired with full receptor immune receptor sequences such that information about the immune repertoire and transcriptome of a cell can be determined. Also provided are polynucleotide libraries for use in carrying out transcriptome analysis and immune molecule, e.g., antibody or TCR, sequencing.

High-throughput polynucleotide library sequencing and transcriptome analysis

Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV 16 E6 and HPV 16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.

HPV-specific binding molecules

Growing community of inventors

Seattle, WA, United States of America

Yue Jiang